Phase I, open-label, dose escalation of AZD4877 in hematologic Malignancies
Study identifier:D2782C00002
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Terminated/Withdrawn
Official Title
A Phase I, open-label, dose escalation study to assess the safety, tolerability & pharmacokinetics of AZD4877 administered once weekly in adult patients with recurrent or refractory AML, PH negative ALL, NHL or MN
Medical condition
Lymphoma
Phase
Phase 1
Healthy volunteers
No
Study drug
AZD4877
Sex
All
Actual Enrollment
75
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Mar 2007
Primary Completion Date: -
Study Completion Date: 01 Aug 2007
Study design
Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
Judith Ochs
AstraZeneca
